Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FURESTEM-OA + CAM
- Development stage
- Unknown
- Lead developer
- Kangstem Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
FURESTEM-OA + CAM (branded as FURESTEM-OA Kit Inj.) is a combination biologic therapy developed by Kangstem Biotech in collaboration with Heraeus Medical for the treatment of knee osteoarthritis. The product consists of two components: FURESTEM-OA Inj., which contains allogeneic umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), and CAM Inj., a secondary solution. These components are mixed in a disposable syringe and administered as a single intra-articular injection into the knee joint cavity. The therapy is designed to promote cartilage regeneration and reduce inflammation in patients with Kellgren-Lawrence grade 2-3 knee osteoarthritis who have not responded to conservative treatments. It is currently being evaluated in Phase I/IIa clinical trials to determine safety, efficacy, and optimal dosing.
- Brand names
- FURESTEM-OA Kit Inj.
- Other names
- FURESTEM-OA Inj.CAM Inj.PureStem-OAallogeneic umbilical cord blood-derived mesenchymal stem cells
Beyond the preview
Go deeper on FURESTEM-OA + CAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FURESTEM-OA + CAM.